FDA launches one-day inspections

The FDA has started testing a new kind of site visit — a one-day inspectional assessment. This is still an inspection tool, but it is narrower, faster, and more selective than the standard version. The basic problem the agency is trying to solve is simple: there are a lot of facilities to watch, and full inspections take time. So on May 6, 2026, the FDA said it had already launched a pilot in April to see whether short, targeted visits can widen coverage without giving up leverage. ### What is the FDA actually doing? The agency is sending investigators in for shorter screening assessments that are designed to answer focused questions fast, instead of running a full routine inspection every time. The FDA says these one-day assessments are meant to complement its normal inspection program, not replace it, and investigators can still widen the scope or stay longer if they see something concerning. ### Why try this now? Because FDA oversight is already risk-based in practice, but full inspections are expensive in time and staffing. The agency already prioritizes facilities using risk models, prior history, product type, and other signals. A shorter visit gives the FDA another way to check more sites, gather fresher information, and that made sense. ### Which facilities are in the pilot? Not the hardest ones. The FDA says the pilot does not apply to higher-risk or more complex facilities that need comprehensive inspectional coverage. Instead, facilities are being selected with risk-based criteria like product type, prior inspection outcomes, and operational characteristics. The pilot spans multiple inspectorates — human and animal foods, biologics, medical products, and clinical research programs. ### How far along is it already? Far enough that this is not just a concept slide. The pilot started in April 2026, runs through fiscal 2026, and the FDA said that by late April it had already completed about 46 one-day assessments. Most of those ended as No Action Indicated, or NAI, which is FDA shorthand for a site where investigators did not identify objectionable conditions needing regulatory action. ### What happens if investigators find trouble? Then the “one-day” part stops being the point. The FDA says some assessments have already extended beyond one day when significant observations showed up. That matters because industry should not read this as a softer inspection lane. The agency is keeping the same enforcement authority, and if investigators see enough to justify a deeper look, they can turn a quick screen into something more traditional. ### What does industry need to pay attention to? Readiness gets more continuous. A company might not get the long runway or the broader choreography that often comes with a standard inspection. If the FDA is using short visits to validate registration details, operating reality, and recurring compliance themes, then basic documentation, site accuracy, and day-to-day controls matter even more. The catch is that a narrow visit can still surface a big problem fast. ### Why does this matter beyond this pilot? Because it hints at how FDA oversight may scale from here. The agency says data from these assessments can feed stronger risk models — things like facility-specific risk scores, recurring compliance patterns, and gaps between what a site says it does and what investigators actually find. That makes the pilot more than a scheduling tweak. It is also a data-gathering system for deciding who gets the next hard look. ### Bottom line? This is the FDA trying to inspect smarter, not less. For lower-risk sites, that could mean shorter disruption and faster feedback. But it also means the agency may be able to show up more often, across more facilities, with just enough time to decide whether a one-day visit should become something much bigger.